ZEMBRACE SYMTOUCH Drug Patent Profile

Which patents cover Zembrace Symtouch, and when can generic versions of Zembrace Symtouch launch?

Zembrace Symtouch is a drug marketed by Tonix Meds and is included in one NDA. There are three patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in ZEMBRACE SYMTOUCH is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zembrace Symtouch

A generic version of ZEMBRACE SYMTOUCH was approved as sumatriptan succinate by HIKMA on February 6^th, 2009.

Summary for ZEMBRACE SYMTOUCH

International Patents:	6
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,992
Drug Prices:	Drug price information for ZEMBRACE SYMTOUCH
What excipients (inactive ingredients) are in ZEMBRACE SYMTOUCH?	ZEMBRACE SYMTOUCH excipients list
DailyMed Link:	ZEMBRACE SYMTOUCH at DailyMed

See drug prices for ZEMBRACE SYMTOUCH

Pharmacology for ZEMBRACE SYMTOUCH

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

US Patents and Regulatory Information for ZEMBRACE SYMTOUCH

ZEMBRACE SYMTOUCH is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tonix Meds	ZEMBRACE SYMTOUCH	sumatriptan succinate	SOLUTION;SUBCUTANEOUS	208223-001	Jan 28, 2016		RX	Yes	No	10,537,554
Tonix Meds	ZEMBRACE SYMTOUCH	sumatriptan succinate	SOLUTION;SUBCUTANEOUS	208223-001	Jan 28, 2016		RX	Yes	No	11,364,224
Tonix Meds	ZEMBRACE SYMTOUCH	sumatriptan succinate	SOLUTION;SUBCUTANEOUS	208223-001	Jan 28, 2016		RX	Yes	No	12,097,183		Y

International Patents for ZEMBRACE SYMTOUCH

See the table below for patents covering ZEMBRACE SYMTOUCH around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112018002433	composição farmacêutica para tratamento da enxaqueca
Canada	2994748	COMPOSITION PHARMACEUTIQUE COMPRENANT DU SUMATRIPTAN POUR LE TRAITEMENT DE LA MIGRAINE (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE)
China	107921023	用于治疗偏头痛的包含舒马曲坦的药物组合物 (Pharmaceutical composition comprising sumatripan for treating migraine)
European Patent Office	3331524	COMPOSITION PHARMACEUTIQUE COMPRENANT DU SUMATRIPTAN POUR LE TRAITEMENT DE LA MIGRAINE (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE)

Zembrace SymTouch (sumatriptan injection) market dynamics and financial trajectory: pricing pressure, channel mix, and exclusivity-to-generic transition

Last updated: May 31, 2026

Zembrace SymTouch (sumatriptan) revenue has tracked a post-launch contraction pattern typical for branded injectables after channel normalization and competitive substitution. The market has also been shaped by payer preference for lower-cost sumatriptan options, intermittent inventory effects from supply and distribution, and the timing of patent and regulatory exclusivity cliffs. Financial trajectory for Zembrace SymTouch is therefore best analyzed as a branded “value erosion” story, where growth windows are short and price declines dominate as soon as multiple competitively priced alternatives are available.

How has Zembrace SymTouch performed commercially versus other sumatriptan injectables?

Zembrace SymTouch is a branded subcutaneous (SC) sumatriptan product marketed for acute migraine treatment. In the US, its commercial ceiling has been constrained by the long-standing availability of generic sumatriptan injectables and other delivery formats (including autoinjector-ready equivalents where available). As a result, the core market dynamic is not “new patient share growth” but payers and wholesalers optimizing acquisition cost.

What drives Zembrace SymTouch demand in US acute migraine treatment?

Commercial demand for branded SC triptans generally depends on:

• payer step edits and preferred drug lists that steer to generics when clinically acceptable
• administered convenience and adherence impact versus manual injection alternatives
• patient and prescriber preference where switching friction is lower

For migraine acute care, utilization is also seasonally and attack-frequency driven, so incremental share can exist even during brand price compression, but total addressable spend tends to decline as the cheapest options win formulary share.

What share of spend is typically “protected” for brands in this category?

In triptans, brands often retain limited pockets of protected share through:

• formulary tiering (preferred brand vs. non-preferred generic)
• patient assistance support
• prescriber preference in specific populations needing SC dosing continuity

For Zembrace SymTouch, these pockets usually shrink over time as payers update contracts and as equivalent SC offerings broaden.

---

What is the price and reimbursement trajectory for Zembrace SymTouch after generic entry?

Zembrace SymTouch’s financial trajectory is tightly coupled to net price evolution after substitution pressure. The unit economics for branded triptans usually degrade through:

• wholesaler charge and reimbursement changes
• payer contract resets that compress acquisition cost differentials
• co-pay dynamics that become less favorable as patient assistance is tightened

Where does revenue go after price cuts in branded triptans?

When list and net prices decline, volume is rarely enough to fully offset revenue loss unless:

• utilization expands meaningfully, or
• the product retains durable formulary placement as a preferred SC option

For Zembrace SymTouch, the category’s generic penetration makes net revenue preservation difficult without distinct access advantages.

---

When does Zembrace SymTouch lose exclusivity, and how does that affect revenue?

The exclusivity-to-generic transition is the central financial inflection mechanism for branded injectables with multiple generic entry opportunities. For migraine injectables, the practical timeline often includes:

• patent/market exclusivity windows that slow generic launches
• then a stepwise decline as multiple ANDA competitors come on line
• then a further erosion as payer contracts reprice around the lowest net-cost options

What are the typical revenue impacts at each stage?

• Pre-exclusivity: slower competitive pressure, stable net price relative to generics.
• At first generic launches: immediate net price pressure and inventory channel digestion.
• 6 to 18 months after generic launches: broader formulary and pharmacy switching drives continued decline.

---

**What patent estate and Orange Book status affect Zembrace SymTouch’s market?

Zembrace SymTouch’s ability to sustain a branded price premium depends on what is still protected in the Orange Book: active ingredient, formulation, device features (where claimed), and method-of-use, if any.

What patent types usually matter most for sumatriptan injectables?

In this drug class, the most relevant segments of protection typically include:

• process and composition-of-matter claims around the drug substance
• formulation claims around the injection composition
• device-related claims if an autoinjector or specific delivery system is claimed
• use claims if a narrower clinical profile is protected

How does patent landscape translate into launch barriers for generics?

A generic entrant typically has to navigate:

• FDA ANDA eligibility and bioequivalence requirements
• infringement risk based on Orange Book-listed patents
• potential Paragraph IV litigation outcomes

For brands like Zembrace SymTouch, even if basic generics exist, additional formulation or device-related patents can delay certain substitutes or shift the “closest” competitor strategy.

---

Which generic or biosimilar entry risks exist for Zembrace SymTouch?

Sumatriptan is a small molecule, so “biosimilar risk” does not apply. The relevant competitive risk is generic small-molecule ANDA entry.

What generic entry scenarios usually occur for branded injectables?

Common scenarios include:

• first-wave generic approval followed by multiple label-claiming competitors
• substitution at pharmacy level after wholesaler stocking changes
• payer switching after contract expiration cycles

What tends to drive the fastest branded revenue deterioration?

• multiple ANDAs approved within a short window
• payer preferred-tier switches that force pharmacy substitution
• net price resets that reduce the branded differential

---

What Paragraph IV challenges affect Zembrace SymTouch, and how do they change launch timing?

The financial impact of Paragraph IV depends on:

• whether litigation includes stays that delay FDA approval
• settlement design that can delay some entrants while allowing others
• how quickly customers switch once generics reach the market

How do settlements usually reshape revenue outcomes for Zembrace SymTouch?

Settlements can:

• postpone entry of specific challengers for defined periods
• allow earlier launches from non-settled competitors
• create conditional launch triggers tied to patent expiration dates

For revenue, the net effect is often a “delayed but still inevitable price compression” rather than full brand durability.

---

What FDA regulatory milestones influence Zembrace SymTouch supply and sales?

FDA milestones influence branded performance through launch cadence, labeling scope, and supply continuity.

Which regulatory events matter most for branded injectables?

• ANDA approvals in the same presentation strengths
• label changes that broaden or narrow usage conditions
• manufacturing site approvals or quality events that affect supply reliability
• discontinuation decisions or device/packaging lifecycle events

---

How does Zembrace SymTouch compare with competitor sumatriptan products on access, pricing, and device?

Zembrace SymTouch’s differentiator is delivery convenience for SC self-administration. Competitors often compete across three dimensions:

1. acquisition cost at pharmacy and contract level
2. device usability and time-to-administer
3. patient and prescriber switching friction

How does device convenience translate into formulary outcomes?

If payers view the SC route as clinically comparable across alternatives, they often prefer lowest net-cost options. Device advantages can matter when:

• the alternative is less convenient, increasing adherence drop-off
• specific subgroups require reliable SC administration
• clinicians document tolerability differences

Without durable clinical differentiation recognized by payers, device convenience usually yields limited long-term economic shelter.

---

What does the revenue trajectory imply about Zembrace SymTouch’s market size and margins?

Branded injectables with broad generic availability typically show:

• declining net revenues
• narrowing gross margin as price pressure increases
• higher working-capital and distribution costs due to lower throughput predictability

This produces a financial pattern where revenue declines are not linear: they often accelerate around contract resets and generic entry waves.

---

Key Takeaways

• Zembrace SymTouch revenue dynamics are dominated by branded price erosion as generics and contract-preferred alternatives expand.
• The main financial inflection points track exclusivity and patent-driven generic launch timing, followed by payer contract repricing cycles.
• Device convenience supports localized share retention but rarely sustains net revenue against broad generic penetration.
• The strongest forecasting signal is the “competition wave” concept: net revenue typically falls fastest when multiple alternatives become simultaneously accessible via pharmacy stocking and preferred-tier contracting.

FAQs

1. Is Zembrace SymTouch still a formulary option in the US after generic sumatriptan entry?
2. What is the fastest revenue erosion mechanism for branded sumatriptan injectables: price cuts, volume loss, or payer contract switches?
3. Do settlements in Paragraph IV cases for sumatriptan injectables delay all generic launches or only specific challengers?
4. How do device-related factors (SC self-injection versus other delivery forms) change payer preference for Zembrace SymTouch?
5. What FDA and Orange Book events most directly change the near-term sales outlook for Zembrace SymTouch?

References

1. FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026).
2. FDA Drug Approvals and Databases. U.S. Food and Drug Administration. (Accessed 2026).